본문 바로가기
KERD
논문KCI 등재

Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration

김나래|진희승|이강훈|문연성
대한안과학회 (The Korean Ophthalmological Society)|2015.12|Korean Journal of Ophthalmology|제29권 제6호|pp. 396-403

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Optical coherence tomographyNeovascular age-related macular degenerationRanibizumabAnti-vascular endothelial growth factorVitreomacular traction
주제분류안과학

초록

Purpose: To investigate the effects of vitreomacular traction (VMT) on ranibizumab treatment response for neovascularage-related macular degeneration (AMD). Methods: A retrospective review of 85 eyes of 85 patients newly diagnosed with neovascular AMD was conducted. Patients were eligible if they had received more than three consecutive monthly ranibizumab (0.50 mg)treatments and ophthalmic evaluations. Patients were classified into a VMT (+) group or VMT (-) group accordingto optical coherence tomography imaging. Best corrected visual acuity and central retinal thickness (CRT)measurements were obtained at three and six months after initial injection. Results: One month after the third injection, mean visual acuity (VA) increases of 6.36 and 9.87 letters were observedin the VMT (+) and VMT (-) groups, respectively. The corresponding mean CRT values decreased by70.29 μm and 121.68 μm, respectively. A total 41 eyes were identified as eligible for a subsequent fourth injection;71.1% of patients (27 eyes) in the VMT (+) group but only 29.8% of patients in the VMT (-) group needed asubsequent fourth injection. Follow-up was extended to six months for 42 of the 85 enrolled patients (49.4%). The trends in VA and optical coherence tomography were found to be maintained at six-month follow-up. Conclusions: VA and CRT appeared to be more improved after ranibizumab treatment in the VMT (-) groupcompared to the VMT (+) group. VMT might antagonize the effect of ranibizumab treatment in a subpopulationof AMD patients.

Abstract

Purpose: To investigate the effects of vitreomacular traction (VMT) on ranibizumab treatment response for neovascularage-related macular degeneration (AMD). Methods: A retrospective review of 85 eyes of 85 patients newly diagnosed with neovascular AMD was conducted. Patients were eligible if they had received more than three consecutive monthly ranibizumab (0.50 mg)treatments and ophthalmic evaluations. Patients were classified into a VMT (+) group or VMT (-) group accordingto optical coherence tomography imaging. Best corrected visual acuity and central retinal thickness (CRT)measurements were obtained at three and six months after initial injection. Results: One month after the third injection, mean visual acuity (VA) increases of 6.36 and 9.87 letters were observedin the VMT (+) and VMT (-) groups, respectively. The corresponding mean CRT values decreased by70.29 μm and 121.68 μm, respectively. A total 41 eyes were identified as eligible for a subsequent fourth injection;71.1% of patients (27 eyes) in the VMT (+) group but only 29.8% of patients in the VMT (-) group needed asubsequent fourth injection. Follow-up was extended to six months for 42 of the 85 enrolled patients (49.4%). The trends in VA and optical coherence tomography were found to be maintained at six-month follow-up. Conclusions: VA and CRT appeared to be more improved after ranibizumab treatment in the VMT (-) groupcompared to the VMT (+) group. VMT might antagonize the effect of ranibizumab treatment in a subpopulationof AMD patients.

참고문헌 (57)

  1. Ferrara N, "Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration", Retina, 26, pp.859~870 (2006)
  2. Ferrara N, "Targeting VEGF-A to treat cancer and age-related macular degeneration", Annu Rev Med, 58, pp.491~504 (2007)
  3. Witmer AN, "Vascular endothelial growth factors and angiogenesis in eye disease", Prog Retin Eye Res, 22, pp.1~29 (2003)
  4. Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
  5. Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
  6. Regillo CD, "Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1", Am J Ophthalmol, 145, pp.239~248 (2008)
  7. Schmidt-Erfurth U, "Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study", Ophthalmology, 118, pp.831~839 (2011)
  8. Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
  9. Holz FG, "Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study", Ophthalmology, 118, pp.663~671 (2011)
  10. CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
  11. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results", Ophthalmology, 119, pp.1388~1398 (2012)
  12. IVAN Study Investigators, "Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial", Ophthalmology, 119, pp.1399~1411 (2012)
  13. Lim JH, "Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration", Am J Ophthalmol, 153, pp.678~686 (2012)
  14. Lux A, "Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions", Br J Ophthalmol, 91, pp.1318~1322 (2007)
  15. Teper SJ, "Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration", Mol Vis, 16, pp.2598~2604 (2010)
  16. Klein RJ, "Complement factor H polymorphism in age-related macular degeneration", Science, 308, pp.385~389 (2005)
  17. Dewan A, "HTRA1 promoter polymorphism in wet age-related macular degeneration", Science, 314, pp.989~992 (2006)
  18. Mori K, "Association of the HTRA1 gene variant with age-related macular degeneration in the Japanese population", J Hum Genet, 52, pp.636~641 (2007)
  19. Krebs I, "Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration", Br J Ophthalmol, 95, pp.1415~1418 (2011)
  20. Ondes F, "Role of the vitreous in age-related macular degeneration", Jpn J Ophthalmol, 44, pp.91~93 (2000)
  21. Krebs I, "Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration?", Am J Ophthalmol, 144, pp.741~746 (2007)
  22. Schulze S, "Vitreomacular traction and exudative age-related macular degeneration", Acta Ophthalmol, 86, pp.470~481 (2008)
  23. Mojana F, "The role of abnormal vitreomacular adhesion in age-related macular degeneration:spectral optical coherence tomography and surgical results", Am J Ophthalmol, 146, pp.218~227 (2008)
  24. Lee SJ, "Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration:paired eye study", Am J Ophthalmol, 147, pp.621~626 (2009)
  25. Lee SJ, "Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration", Ophthalmology, 118, pp.101~110 (2011)
  26. Mathew R, "Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab", Am J Ophthalmol, 155, pp.720~726 (2013)
  27. Green-Simms AE, "Vitreomacular traction and age-related macular degeneration", Semin Ophthalmol, 26, pp.137~138 (2011)
  28. Simpson AR, "Vitreomacular adhesion and neovascular age-related macular degeneration", Surv Ophthalmol, 57, pp.498~509 (2012)
  29. Maier M, "Vitreomacular interface and posterior vitreomacular adhesion in exudative age-related macular degeneration (AMD): an OCT-based comparative study", Klin Monbl Augenheilkd, 229, pp.1030~1035 (2012)
  30. Jackson TL, "Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis", Retina, 33, pp.1099~1108 (2013)
  31. Weber-Krause B, "Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration: an ultrasonic study", Ophthalmologe, 93, pp.660~665 (1996)
  32. Yannuzzi LA, "Digital indocyanine green videoangiography and choroidal neovascularization", Retina, 32(1), pp.191~ (2012)
  33. Yannuzzi LA, "Idiopathic polypoidal choroidal vasculopathy (IPCV)", Retina, 10, pp.1~8 (1990)
  34. Ross RD, "Idiopathic polypoidal choroidal vasculopathy associated with retinal arterial macroaneurysm and hypertensive retinopathy", Retina, 16, pp.105~111 (1996)
  35. Stangos AN, "Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab", Am J Ophthalmol, 150, pp.666~673 (2010)
  36. Adamis AP, "The role of vascular endothelial growth factor in ocular health and disease", Retina, 25, pp.111~118 (2005)
  37. Seko Y, "Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro", Invest Ophthalmol Vis Sci, 40, pp.3287~3291 (1999)
  38. Meyer CH, "Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature", Graefes Arch Clin Exp Ophthalmol, 239, pp.325~333 (2001)
  39. Stefansson E, "Physiology of vitreous surgery", Graefes Arch Clin Exp Ophthalmol, 247, pp.147~163 (2009)
  40. Reese AB, "Macular changes secondary to vitreous traction", Am J Ophthalmol, 64, pp.544~549 (1967)
  41. Spaide RF, "Continuing medical education review: choroidal neovascularization in age-related macular degeneration: what is the cause?", Retina, 23, pp.595~614 (2003)
  42. Rotsos T, "Intravitreal anti-VEGF treatment in eyes with combined choroidal neovascularisation and vitreomacular traction syndrome", Br J Ophthalmol, 94, pp.1205~1210 (2010)
  43. Ozsutcu M, "Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous", Case Rep Ophthalmol, 4, pp.7~10 (2013)
  44. Manousaridis K, "Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?", Br J Ophthalmol, 96, pp.179~184 (2012)
  45. Mendrinos E, "Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration", Acta Ophthalmol, 91, pp.184~190 (2013)
  46. Papadopoulou DN, "Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration", Ophthalmology, 116, pp.1755~1761 (2009)
  47. Marneros AG, "Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function", Am J Pathol, 167, pp.1451~1459 (2005)
  48. Peters S, "Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab", Am J Ophthalmol, 143, pp.995~1002 (2007)
  49. Shah SU, "Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy", Acta Ophthalmol, 90, pp.569~570 (2012)
  50. Kakinoki M, "Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys", Invest Ophthalmol Vis Sci, 53, pp.5877~5880 (2012)
  51. Christoforidis JB, "Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy", Retina, 33, pp.946~952 (2013)
  52. Stalmans P, "Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes", N Engl J Med, 367, pp.606~615 (2012)
  53. Stalmans P, "Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis", Retina, 33, pp.2003~2011 (2013)
  54. Anderson DH, "A role for local inflammation in the formation of drusen in the aging eye", Am J Ophthalmol, 134, pp.411~431 (2002)
  55. Donoso LA, "The role of inflammation in the pathogenesis of age-related macular degeneration", Surv Ophthalmol, 51, pp.137~152 (2006)
  56. Zarbin MA, "Current concepts in the pathogenesis of age-related macular degeneration", Arch Ophthalmol, 122, pp.598~614 (2004)
  57. Ryan SJ, "Retina" (2001), Mosby

관련 논문AI추천

Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration권오웅, 권윤형, 김형은, 이동규대한안과학회 · Korean Journal of Ophthalmology2014 · 제28권 제5호Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography박규형, 신주영, 안지윤, 우세준대한안과학회 · Korean Journal of Ophthalmology2013 · 제27권 제6호Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical ExperienceAbdullah Ozkaya, Irfan Perente, Mesut Togac, Muhittin Taskapili, Sibel Ahmet, Zeynep Alkin대한안과학회 · Korean Journal of Ophthalmology2017 · 제31권 제5호Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity김재희, 류영주, 유수진, 장용석, 한정일대한안과학회 · Korean Journal of Ophthalmology2014 · 제28권 제6호Short-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance Study우세준, Ga Eun Cho, Joon Hee Cho대한안과학회 · Korean Journal of Ophthalmology2019 · 제33권 제2호Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion곽형우, 김응석, 손보권, 유승영대한안과학회 · Korean Journal of Ophthalmology2017 · 제31권 제3호

이 간행물의 다른 논문 (13건)

An Overview of Ophthalmologic Survey Methodology in the 2008- 2015 Korean National Health and Nutrition Examination Surveys백승희, 김찬윤, 유승영, 강세웅, 신재필, 윤경철, 이종수, 박기호, 송수정, 김승현, 최원, 김상덕, 박영정, 임기환, 양석우, 이효석, 오경원pp. 359-367Surgical Outcomes of Canalicular Trephination Combined with Endoscopic Dacryocystorhinostomy in Patients with Distal or Common Canalicular Obstruction공윤진, 장선영, 김성주, 최혜선, 장재우pp. 368-374A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery최상경, 황신영pp. 375-381Comparison of Serum Cortisol and Testosterone Levels in Acute and Chronic Central Serous ChorioretinopathyAvonuo Keditsu, Tanie Natungpp. 382-388Comparison of the Clinical Manifestations between Acute Vogt- Koyanagi-Harada Disease and Acute Bilateral Central Serous Chorioretinopathy이승규, 김혜선, 이성철, 김민교, 신우범pp. 389-395
원문 보기